Summary & Overview
CPT 45520: Injection of Sclerosant for Prolapsed Rectal Mucosa
CPT code 45520 denotes injection of a sclerosant into prolapsed rectal mucosa, a minimally invasive proctologic procedure to induce scarring and reduce prolapse. Nationally, this code captures a commonly used nonsurgical or adjunctive treatment for internal hemorrhoidal disease and mucosal prolapse, offering a lower-resource alternative to operative repair for selected patients.
Key payers in this review include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Coverage and coding practices for 45520 vary across commercial and public payers and can affect site-of-service selection and prior authorization requirements.
Readers will learn the clinical context and service setting for 45520, payer coverage considerations, common billing modifiers, and related coding issues. The publication provides benchmarks for utilization and reimbursement patterns where available, outlines policy implications for outpatient procedural management of rectal prolapse and hemorrhoidal disease, and summarizes documentation elements relevant to accurate coding. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 45520 describes the injection of a sclerosant (a chemical irritant) to treat prolapsed mucosa of the rectum. The procedure involves directly injecting the agent into the prolapsed tissue to induce fibrosis and reduce prolapse.
Service type: Procedural — perineal/rectal office or ambulatory procedure
Typical site of service: Ambulatory surgical center, office-based procedural suite, or outpatient clinic specializing in colorectal or proctologic care
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult presenting to a colorectal clinic with symptomatic internal hemorrhoids characterized by prolapsed mucosa causing bleeding, discomfort, and difficulty with hygiene. After history and physical exam including anoscopy or proctoscopy confirming prolapsed mucosal hemorrhoids suitable for non-surgical management, the provider discusses sclerotherapy as a minimally invasive office-based option. The procedure workflow: consent and pre-procedure vitals are obtained; the patient is positioned in left lateral or prone jackknife; anoscopic visualization identifies the target prolapsed mucosa; a sclerosant (chemical irritant) is injected into the submucosal tissue of the prolapsed hemorrhoidal cushions; hemostasis and post-injection inspection are performed; recovery includes brief observation, discharge instructions for analgesia and bowel regimen, and follow-up. Typical site of service is an outpatient office or ambulatory surgical center. The service type is a minor therapeutic procedure (sclerotherapy) directed at prolapsed rectal mucosa for hemorrhoidal disease.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Primary procedure | When this sclerotherapy is the primary service on the claim |
22 |